Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings : Episode 1
Identifying Potential Candidates for CAR T-Cell Therapy
A panel of experts on multiple myeloma introduce themselves and discuss the initial process of identifying patients who are potential candidates for CAR T-cell therapy.
Now Viewing
EP: 1.Identifying Potential Candidates for CAR T-Cell Therapy
EP: 2.Treating Patients Referred to Academic Centers for CAR T
EP: 3.CAR T-Cell Therapy: Leukapheresis Practices
EP: 4.Triaging and Prioritizing Patients with Multiple Myeloma
EP: 5.Transitioning Patients Back to Community Practices Following CAR T
EP: 6.Monitoring Adverse Events Following CAR T-Cell Therapy
EP: 7.Educating Patients on Complications Associated with CAR T-Cell Therapy
EP: 8.Improving Access for Patients Receiving CAR T-Cell Therapy
EP: 9.Collaborative Education for CAR T-Cell Therapy
EP: 10.Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
- Could you describe the initial process of identifying and referring potential candidates for CAR T-cell therapy from the community setting to an academic center?
- What patient specific factors might you consider?
- Are there any criteria that patients need to meet in order to be ready to move to a community setting?Does this vary between community settings?
- What are some challenges you are seeing when transitioning from community to academic settings?
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
